期刊
TRENDS IN MOLECULAR MEDICINE
卷 20, 期 11, 页码 643-651出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2014.09.004
关键词
epithelial plasticity; epithelial-mesenchymal transition; mesenchymal-epithelial transition; androgen receptor; androgen deprivation therapy; chemotherapy
资金
- Prostate Cancer Foundation (Foundation 14 Award)
- Prostate Cancer Foundation of Australia (PCFA) [YI 0810]
- PCFA/Cancer Australia [1012337, 1043482]
- Ray and Shirl Norman Cancer Research Trust
- Cancer Council of South Australia
- Queensland government Smart Futures Fund Fellowship
- Movember Foundation
- Prostate Cancer Foundation of Australia through a Movember Revolutionary Team
- PCFA [2011/0452]
Over the past decade, the capacity of cancer cells to oscillate between epithelial and mesenchymal phenotypes, termed epithelial plasticity (EP), has been demonstrated to play a critical role in metastasis. This phenomenon may be particularly important for prostate cancer (PC) progression, since recent studies have revealed interplay between EP and signaling by the androgen receptor (AR) oncoprotein. Moreover, EP appears to play a role in dictating the response to therapies for metastatic PC. This review will evaluate preclinical and clinical evidence for the relevance of EP in PC progression and consider the potential of targeting and measuring EP as a means to treat and manage lethal forms of the disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据